Annals of Neurology · 2005 · 160 citations · 25 references
Life SciencesNeurologyNeuroscienceDementiaNeurochemistryNeurodegenerationAlzheimer DiseaseBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer Disease DementiaAlzheimer Disease Tau PathologyAlzheimer's Disease DiagnosisCerebrospinal Fluid MarkersCerebrospinal Fluid Neurodegeneration MarkersCerebrospinal Fluid TauMolecular Diagnostic MarkersTau Protein Biomarkers
Alzheimer's disease, the most common cause of dementia, is multifactorial and heterogeneous; its diagnosis remains probable. We postulated that more than one disease mechanism yielded Alzheimer's histopathology, and that subgroups of the disease might be identified by the cerebrospinal fluid (CSF) levels of proteins associated with senile (neuritic) plaques and neurofibrillary tangles. We immunoassayed levels of tau, ubiquitin, and Abeta(1-42) in retrospectively collected CSF samples of 468 clinically diagnosed Alzheimer's disease patients (N = 353) or non-Alzheimer's subjects (N = 115). Latent profile analysis assigned each subject to a cluster based on the levels of these molecular markers. Alzheimer's disease was subdivided into at least five subgroups based on CSF levels of Abeta(1-42), tau, and ubiquitin; each subgroup presented a different clinical profile. These subgroups, which can be identified by CSF analysis, might benefit differently from different therapeutic drugs.
25
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Suzanne S. Mirra, Albert Heyman, Daniel W. McKeel et al. · Neurology · 1991 · 5.1K citations